rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

MIRA Pharmaceuticals, Inc.

MIRA · Nasdaq

Health CareBiotechnologyNot moving yet

MIRA stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 39 weeks. It is 29.2% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 39
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
25 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders25-1 on the quarter
New · exited3 · 4
Reported value$2.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026751,801$712K+57,889+8.3%
Cross Staff Investments Incunchanged · filed 22 Jul 2026359,401$340K00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026303,882$288K+12,992+4.5%
BlackRock, Inc.added · filed 7 Aug 2026244,622$232K+132,276+117.7%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026170,668$162K+1,185+0.7%
CAPTRUST FINANCIAL ADVISORSnew · filed 13 Aug 202690,645$86K+90,645
NORTHERN TRUST CORPadded · filed 13 Aug 202667,735$64K+37+0.1%
FIRST AMERICAN BANKunchanged · filed 15 Jul 202660,000$57K00.0%
COMMONWEALTH EQUITY SERVICES, LLCadded · filed 29 Jul 202653,189$50K+18,122+51.7%
STATE STREET CORPunchanged · filed 7 Aug 202649,100$46K00.0%
30 Sep 2023 – 30 Jun 2026
41526Sep 23Jun 24Mar 25Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Denil Nanji Shekhat Company insiderDirector · last 12 Jun 20260 · 0
Edward Clouston MacPherson Company insiderDirector · last 12 Jun 20260 · 0
Matthew Paul Del Giudice Company insiderDirector · last 12 Jun 20260 · 0
Matthew Pratt Whalen Company insiderDirector · last 12 Jun 20260 · 0
Erez Aminov Company insiderChief Executive Officer · last 30 Mar 20261 · 3
Michelle Yanez Company insiderChief Financial Officer · last 9 Dec 20240 · 0
Brian Patrick McNulty Company insider10% owner · last 28 Aug 20240 · 12
Michael Allen Jerman Company insiderDirector · last 25 Mar 20240 · 0
Christopher C. Chapman, Jr. Company insiderExecutive Chairman · last 17 Aug 20230 · 0
Christos Nicholoudis Company insiderDirector · last 17 Aug 20230 · 0
Bay Shore Trust Company insider10% owner · last 7 Aug 20232 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 30 Mar 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.3M

Analyst forecasts

No analyst forecasts yet.